These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3287024)

  • 21. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
    Keating GM; Ormrod D
    Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dyslipidemia and coronary artery disease.
    Kuo PT
    Clin Cardiol; 1994 Oct; 17(10):519-27. PubMed ID: 8001298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on the management of dyslipidemia.
    Irons BK; Snella KA; McCall K; MacLaughlin EJ; Villarreal M
    Am J Health Syst Pharm; 2002 Sep; 59(17):1615-25. PubMed ID: 12224342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Niacin--an additive therapeutic approach for optimizing lipid profile].
    Wieneke H; Schmermund A; Erbel R
    Med Klin (Munich); 2005 Apr; 100(4):186-92. PubMed ID: 15834527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of lipid disorders in the elderly.
    Playford DA; Watts GF
    Drugs Aging; 1997 Jun; 10(6):444-62. PubMed ID: 9205850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term use of probucol in the multifactorial primary prevention of vascular disease.
    Miettinen TA; Huttunen JK; Naukkarinen V; Strandberg T; Vanhanen H
    Am J Cardiol; 1986 Jun; 57(16):49H-54H. PubMed ID: 2873740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current, new and future treatments in dyslipidaemia and atherosclerosis.
    Chong PH; Bachenheimer BS
    Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measurement and management of hyperlipidemia for the primary prevention of coronary heart disease.
    Froom J; Froom P; Benjamin M; Benjamin BJ
    J Am Board Fam Pract; 1998; 11(1):12-22. PubMed ID: 9456442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary prevention of cardiovascular disease: implications of lipid-lowering trials.
    Pedersen TR
    J Hypertens Suppl; 1996 Dec; 14(5):S195-200. PubMed ID: 9120679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
    Yim BT; Chong PH
    Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies for minimizing hyperlipidemia after cardiac transplantation.
    Kirklin JK; Benza RL; Rayburn BK; McGiffin DC
    Am J Cardiovasc Drugs; 2002; 2(6):377-87. PubMed ID: 14727953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Choice of cholesterol-lowering drugs.
    Med Lett Drugs Ther; 1991 Jan; 33(835):1-4. PubMed ID: 1984601
    [No Abstract]   [Full Text] [Related]  

  • 37. Beneficial effects of fish liver preparations of sea bass (Lates calcarifer) versus gemfibrozil in high fat diet-induced lipid-intolerant rats.
    Rizvi F; Iftikhar M; George JP
    J Med Food; 2003; 6(2):123-8. PubMed ID: 12935323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating elevated cholesterol levels: the great Satan in perspective.
    Gibaldi M; Kradjan W
    J Clin Pharmacol; 1996 Mar; 36(3):189-97. PubMed ID: 8690811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study.
    Krasuski RA; Devendra GP; Cater G; Whitney EJ
    Am J Med Sci; 2011 May; 341(5):378-82. PubMed ID: 21358314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid-lowering agents in proteinuric diseases.
    Appel GB; Appel AS
    Am J Nephrol; 1990; 10 Suppl 1():110-5. PubMed ID: 2256470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.